First-In-Human Data About the Treatment of Muscle-Invasive Bladder Cancer With Pentixapharm s Lu177-PentixaTher to be Presented at ASCO-GU 2025
Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the American Society of Clinical Oncology's ...
Targeted Oncology3d
What Community Oncologists Should Watch for at ASCO GU 2025
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
PharmiWeb2d
First-In-Human Data about the Treatment of Muscle-…
ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...
Researchers identify structural changes in botox that allow uptake into nerve cells
Researchers at the Center for Life Sciences at the Paul Scherrer Institute PSI have for the first time identified structural ...
Le Lézard1d
$1 Million Awarded to Continue to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer
The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $450,000 to Saar Gill, MD, PhD, of the University ...
Addex Therapeutics Ltd (NASDAQ:ADXN) Sees Large Drop in Short Interest
Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,500 ...
AlphaGalileo4d
How botox enters our cells
Researchers at the Center for Life Sciences at the Paul Scherrer Institute PSI have for the first time identified structural changes in the botulinum ...
Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites
CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...
Le Lézard1d
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZAtm (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZAtm (vimseltinib), a kinase ...
Armed robbery in Revesby4d
Pfizer, Astellas' PADCEV Plus KEYTRUDA Shows Efficacy
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...
pharmaphorum4d
Bayer's pipeline takes a hit as it drops eliapixant
Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant ... endometriosis, overactive bladder and diabetic neuropathic pain. The decision comes just a few ...
UroToday23h
ASCO GU 2025: Discussant: Adjuvant Immunotherapy in High Risk Muscle Invasive Bladder Cancer
GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...